ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,10192
-0,05%
Bitcoin
66.175,10
-1,14%
Brent Oil
83,76
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Canadá
  5. TSXV
  6. Diamedica Therapeutics (DMA)

  7. Diamedica Therapeutics (DMA) Notícias

DMA

DiaMedica Inc. (DMA)

Diamedica Therapeutics
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:TSXV:DMA
DataHoraFonteTítuloCódigoCompanhia
30/07/201409:00Marketwired CanadaDiaMedica to Present at InvestMNt Conference on August 6, 2014TSXV:DMADiamedica Therapeutics
25/07/201417:30Marketwired CanadaDiaMedica Inc. Announces Results of Annual General and Special Meeting of ShareholdersTSXV:DMADiamedica Therapeutics
10/07/201409:30Marketwired CanadaDiaMedica Promotes Mark Robbins to Executive Vice PresidentTSXV:DMADiamedica Therapeutics
08/07/201418:09Marketwired CanadaDiaMedica Announces Stock Option GrantTSXV:DMADiamedica Therapeutics
07/07/201409:30Marketwired CanadaDiaMedica Appoints Rich Pilnik as Chairman of the Board of DirectorsTSXV:DMADiamedica Therapeutics
10/06/201408:30Marketwired CanadaDiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association ConferenceTSXV:DMADiamedica Therapeutics
05/06/201411:22Marketwired CanadaDiaMedica Announces Development UpdateTSXV:DMADiamedica Therapeutics
03/06/201411:56Marketwired CanadaDiaMedica Inc. Appoints Dr. Ralph A. DeFronzo to its Scientific Advisory BoardTSXV:DMADiamedica Therapeutics
27/05/201412:53Marketwired CanadaDiaMedica Announces Completion of Prospectus OfferingTSXV:DMADiamedica Therapeutics
20/05/201417:22Marketwired CanadaDiaMedica Inc. Announces Filing of Final ProspectusTSXV:DMADiamedica Therapeutics
12/05/201419:26Marketwired CanadaDiaMedica Inc. Finalizes Terms of Public OfferingTSXV:DMADiamedica Therapeutics
08/05/201408:05Marketwired CanadaDiaMedica Inc. Provides Update on Public OfferingTSXV:DMADiamedica Therapeutics
25/04/201418:50Marketwired CanadaDiaMedica Inc. Amends the Expiry Date of WarrantsTSXV:DMADiamedica Therapeutics
22/04/201417:05Marketwired CanadaDiaMedica Inc. Announces Public OfferingTSXV:DMADiamedica Therapeutics
17/04/201410:28Marketwired CanadaDiaMedica Inc. to Amend the Expiry Date of WarrantsTSXV:DMADiamedica Therapeutics
15/04/201410:00Marketwired CanadaDiaMedica to Present at the 2014 GTC Diabetes SummitTSXV:DMADiamedica Therapeutics
07/04/201410:07MarketwiredDiaMedica Appoints John Savage as Chief Financial OfficerTSXV:DMADiamedica Therapeutics
25/03/201413:14Marketwired CanadaGranite Creek Cancels Consulting AgreementTSXV:DMADiamedica Therapeutics
19/02/201410:30MarketwiredDiaMedica Files 20-F Registration Statement with U.S. SEC and Provides Clinical UpdateTSXV:DMADiamedica Therapeutics
05/02/201415:15MarketwiredDiaMedica to Present at 16th Annual BIO CEO & Investor ConferenceTSXV:DMADiamedica Therapeutics
22/01/201420:10Marketwired CanadaDiaMedica Inc. Announces Partial Exercise of Over-Allotment OptionTSXV:DMADiamedica Therapeutics
09/01/201411:30MarketwiredDiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic PatientsTSXV:DMADiamedica Therapeutics
03/01/201412:44Marketwired CanadaDiaMedica Inc. Closes Non-Brokered Private PlacementTSXV:DMADiamedica Therapeutics
23/12/201311:26Marketwired CanadaDiaMedica Inc. Announces Completion of $2.6 Million Prospectus OfferingTSXV:DMADiamedica Therapeutics
20/12/201320:50MarketwiredDiaMedica Inc. Announces Results of Annual General and Special MeetingTSXV:DMADiamedica Therapeutics
20/11/201312:11Marketwired CanadaDiaMedica to Present at the 25th Annual Piper Jaffray HealthcareTSXV:DMADiamedica Therapeutics
11/11/201319:00Marketwired CanadaDiaMedica Issues Stock Option GrantTSXV:DMADiamedica Therapeutics
30/10/201310:00Marketwired CanadaDiaMedica's DM199 Named One of the Top Ten Cardiovascular/Metabolic Disease Projects to WatchTSXV:DMADiamedica Therapeutics
30/09/201309:30Marketwired CanadaDiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic PatientsTSXV:DMADiamedica Therapeutics
30/08/201313:03Marketwired CanadaGranite Creek Retains Marketing ConsultantsTSXV:DMADiamedica Therapeutics
 Apresentando as notícias mais relevantes sobre:TSXV:DMA

Seu Histórico Recente

BIT
P1L331
BNP Paribas Issuance
NASDAQ
DSP
Viant Technology
BIT
F17893
Vontobel Financial Produ...
EU
INBXX
Sgam Bxx Inav
BIT
P1ORV2
BNP Paribas Issuance
BIT
P1U7D6
BNP Paribas Issuance
BIT
ESIGMA
ESI
USOTC
WTAIF
WisdomTree Issuer ICAV A... (CE)
GATE
KLIMAUSDT
Klima DAO
AQSE
AIGP.GB
WT Precious Metals
NYSE
ATN
Action Performance
BIT
P1RFC0
BNP Paribas Issuance
USOTC
GFRWF
Greenfire Resources (PK)
NASDAQ
CACSE
Carrier Access
COIN
AUTOOEUR
BOV
RBRX12
Rbr Plus Multiestrategia...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados